NDUFB7
ENSG00000099795
Target class
Enzyme
Chromosome
19
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Limited
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- NDUFB7
- Gene name
- NADH:ubiquinone oxidoreductase subunit B7
- Gene symbol
- NDUFB7
- Protein name
- NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7 (Cell adhesion protein SQM1) (Complex I-B18) (CI-B18) (NADH-ubiquinone oxidoreductase B18 subunit)
- B18
- CI-B18
- MGC2480
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase supernumerary subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Highest tissue expression
- 327.11
- Tissue specificity (Gini)
- 0.117
- Tissue specificity (tau)
- 0.29
- KEGG gene identifiers
- hsa:4713
- Protein interaction confidence
- 0.909333
- Protein interaction partners
- 117
- R-HSA-611105
- R-HSA-6799198
- End position
- 14572066
- Start position
- 14566078
- Chromosome
- 19
- Strand
- Reverse
- Mitochondrion inner membrane
- Peripheral membrane protein . Mitochondrion intermembrane space .
Publication evidence
- PubMed 21310150
- Tissue specificity (tau)
- 0.289814
- Expression inequality (Gini)
- 0.116776
Expression in transcripts per million
- Artery - Aorta
- 327.11
- Muscle - Skeletal
- 324.6
- Artery - Tibial
- 323.79
- Heart - Left Ventricle
- 315.61
- Colon - Sigmoid
- 312.92
Expression in transcripts per million
- Artery - Aorta327.11
- Muscle - Skeletal324.6
- Artery - Tibial323.79
- Heart - Left Ventricle315.61
- Colon - Sigmoid312.92
- Heart - Atrial Appendage310.72
- Thyroid305.71
- Artery - Coronary295
- Kidney - Medulla272.92
- Esophagus - Gastroesophageal Junction271.17
- Fallopian Tube270.86
- Brain - Cerebellar Hemisphere270.56
- Cervix - Ectocervix269.83
- Esophagus - Muscularis267.56
- Uterus261.76
- Pituitary256.83
- Colon - Transverse255.58
- Cervix - Endocervix254.32
- Nerve - Tibial252.57
- Brain - Frontal Cortex (BA9)250.48
- Cells - Cultured fibroblasts247.81
- Adipose - Subcutaneous245.12
- Prostate239.58
- Esophagus - Mucosa236.09
- Breast - Mammary Tissue234.58
And 29 more, listed on the interactive page.
- GO:0005739
- GO:0005743
- GO:0005758
- GO:0045271
- GO:0005515
- GO:0008137
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor